Unraveling the mystery of cancer metabolism in the genesis of tumor-initiating cells and development of cancer

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1836, Issue 1, 2013, Pages 49-59

  Zhang, Gaochuan ^b   Yang, Ping ^a   Guo, Pengda ^a   Miele, Lucio ^c   Sarkar, Fazlul H ^d   Wang, Zhiwei ^a,e   Zhou, Quansheng ^a,b  

^a THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^b SOOCHOW UNIVERSITY   (China)

^c UNIVERSITY OF MISSISSIPPI   (United States)

^d WAYNE STATE UNIVERSITY   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Cancer metabolism; Cancer therapy; Oncogenic metabolic genes; Stem cells

Indexed keywords

2 HYDROXYGLUTARIC ACID; ADENYLATE KINASE; ALDEHYDE DEHYDROGENASE ISOENZYME 2; BCR ABL PROTEIN; GLUCOSE; GLUTAMINE; GLYCINE; GLYCINE DEHYDROGENASE (DECARBOXYLATING); HERMES ANTIGEN; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; KYNURENINE; LACTIC ACID; MAMMALIAN TARGET OF RAPAMYCIN; MICRORNA; MYC PROTEIN; NON RECEPTOR PROTEIN TYROSINE PHOSPHATASE 4; OCTAMER TRANSCRIPTION FACTOR 4; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PIWI INTERACTING RNA; PROTEIN KINASE B; PROTEIN KINASE LKB1; PROTEIN P53; PROTEIN TYROSINE KINASE; PYRUVATE KINASE; RAF PROTEIN; RAS PROTEIN; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR SOX2;

ACIDITY; AMINO ACID METABOLISM; ANAEROBIC METABOLISM; CANCER CELL; CARCINOGENESIS; CELL HYPOXIA; ENVIRONMENTAL FACTOR; EPIGENETICS; GENE MUTATION; GENE OVEREXPRESSION; GLUCOSE METABOLISM; HUMAN; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; OXIDATIVE PHOSPHORYLATION; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; REVIEW;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; HUMANS; METABOLISM; NEOPLASMS; NEOPLASTIC STEM CELLS; OXIDATIVE PHOSPHORYLATION;

EID: 84876322531     PISSN: 0304419X     EISSN: 18792561     Source Type: Journal    
DOI: 10.1016/j.bbcan.2013.03.001     Document Type: Review

References (170)

1. Warburg O., Wind F., Negelein E. The metabolism of tumors in the body. J. Gen. Physiol. 1927, 8:519-530.
2. Warburg O. On the origin of cancer cells. Science 1956, 123:309-314.
3. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
4. Ward P.S., Thompson C.B. Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. Cancer Cell 2012, 21:297-308.
5. Bonnet D., Dick J.E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med. 1997, 3:730-737.
6. Clarke M.F., Dick J.E., Dirks P.B., Eaves C.J., Jamieson C.H., Jones D.L., Visvader J., Weissman I.L., Wahl G.M. Cancer stem cells-perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res. 2006, 66:9339-9344.
7. Driessens G., Beck B., Caauwe A., Simons B.D., Blanpain C. Defining the mode of tumour growth by clonal analysis. Nature 2012, 488:527-530.
8. Chen J., Li Y., Yu T.S., McKay R.M., Burns D.K., Kernie S.G., Parada L.F. A restricted cell population propagates glioblastoma growth after chemotherapy. Nature 2012, 488:522-526.
9. Levine A.J., Puzio-Kuter A.M. The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes. Science 2010, 330:1340-1344.
10. Oermann E.K., Wu J., Guan K.L., Xiong Y. Alterations of metabolic genes and metabolites in cancer. Semin. Cell Dev. Biol. 2012, 23:370-380.
11. Zhang W.C., Shyh-Chang N., Yang H., Rai A., Umashankar S., Ma S., Soh B.S., Sun L.L., Tai B.C., Nga M.E., Bhakoo K.K., Jayapal S.R., Nichane M., Yu Q., Ahmed D.A., Tan C., Sing W.P., Tam J., Thirugananam A., Noghabi M.S., Pang Y.H., Ang H.S., Mitchell W., Robson P., Kaldis P., Soo R.A., Swarup S., Lim E.H., Lim B. Glycine decarboxylase activity drives non-small cell lung cancer tumor-initiating cells and tumorigenesis. Cell 2012, 148:259-272.
12. Koppenol W.H., Bounds P.L., Dang C.V. Otto Warburg's contributions to current concepts of cancer metabolism. Nat. Rev. Cancer 2011, 11:325-337.
13. Zhang G., Shang B., Yang P., Cao Z., Pan Y., Zhou Q. Induced pluripotent stem cell consensus genes: implication for the risk of tumorigenesis and cancers in induced pluripotent stem cell therapy. Stem Cells Dev. 2012, 21:955-964.
14. Vincent A., Van Seuningen I. On the epigenetic origin of cancer stem cells. Biochim. Biophys. Acta 2012, 1826:83-88.
15. Dominy J.E., Vazquez F., Puigserver P. Glycine decarboxylase cleaves a "malignant" metabolic path to promote tumor initiation. Cancer Cell 2012, 21:143-145.
16. Luo W., Semenza G.L. Emerging roles of PKM2 in cell metabolism and cancer progression. Trends Endocrinol. Metab. 2012, 23:560-566.
17. Luo W., Hu H., Chang R., Zhong J., Knabel M., O'Meally R., Cole R.N., Pandey A., Semenza G.L. Pyruvate kinase M2 is a PHD3-stimulated coactivator for hypoxia-inducible factor 1. Cell 2011, 145:732-744.
18. Tamada M., Nagano O., Tateyama S., Ohmura M., Yae T., Ishimoto T., Sugihara E., Onishi N., Yamamoto T., Yanagawa H., Suematsu M., Saya H. Modulation of glucose metabolism by CD44 contributes to antioxidant status and drug resistance in cancer cells. Cancer Res. 2012, 72:1438-1448.
19. Gao X., Wang H., Yang J.J., Liu X., Liu Z.R. Pyruvate kinase M2 regulates gene transcription by acting as a protein kinase. Mol. Cell 2012, 45:598-609.
20. Yang W., Xia Y., Hawke D., Li X., Liang J., Xing D., Aldape K., Hunter T., Alfred Y.W., Lu Z. PKM2 phosphorylates histone h3 and promotes gene transcription and tumorigenesis. Cell 2012, 150:685-696.
21. Ye J., Mancuso A., Tong X., Ward P.S., Fan J., Rabinowitz J.D., Thompson C.B. Pyruvate kinase M2 promotes de novo serine synthesis to sustain mTORC1 activity and cell proliferation. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:6904-6909.
22. Yang W., Xia Y., Ji H., Zheng Y., Liang J., Huang W., Gao X., Aldape K., Lu Z. Nuclear PKM2 regulates beta-catenin transactivation upon EGFR activation. Nature 2011, 480:118-122.
23. Vander H.M., Locasale J.W., Swanson K.D., Sharfi H., Heffron G.J., Amador-Noguez D., Christofk H.R., Wagner G., Rabinowitz J.D., Asara J.M., Cantley L.C. Evidence for an alternative glycolytic pathway in rapidly proliferating cells. Science 2010, 329:1492-1499.
24. Keller K.E., Tan I.S., Lee Y.S. SAICAR stimulates pyruvate kinase isoform M2 and promotes cancer cell survival in glucose-limited conditions. Science 2012, 338:1069-1072.
25. Yang W., Zheng Y., Xia Y., Ji H., Chen X., Guo F., Lyssiotis C.A., Aldape K., Cantley L.C., Lu Z. ERK1/2-dependent phosphorylation and nuclear translocation of PKM2 promotes the Warburg effect. Nat. Cell Biol. 2012, 14:1295-1304.
26. Clendening J.W., Pandyra A., Boutros P.C., El G.S., Khosravi F., Trentin G.A., Martirosyan A., Hakem A., Hakem R., Jurisica I., Penn L.Z. Dysregulation of the mevalonate pathway promotes transformation. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:15051-15056.
27. Cates C.A., Michael R.L., Stayrook K.R., Harvey K.A., Burke Y.D., Randall S.K., Crowell P.L., Crowell D.N. Prenylation of oncogenic human PTP(CAAX) protein tyrosine phosphatases. Cancer Lett. 1996, 110:49-55.
28. Diamond R.H., Cressman D.E., Laz T.M., Abrams C.S., Taub R. PRL-1, a unique nuclear protein tyrosine phosphatase, affects cell growth. Mol. Cell. Biol. 1994, 14:3752-3762.
29. Kubota Y., Shuin T., Yao M., Inoue H., Yoshioka T. The enhanced 32P labeling of CDP-diacylglycerol in c-myc gene expressed human kidney cancer cells. FEBS Lett. 1987, 212:159-162.
30. Ahuja P., Zhao P., Angelis E., Ruan H., Korge P., Olson A., Wang Y., Jin E.S., Jeffrey FM F.M., Portman M., Maclellan W.R. Myc controls transcriptional regulation of cardiac metabolism and mitochondrial biogenesis in response to pathological stress in mice. J Clin Invest. 2010, 120:1494-1505.
31. Osthus R.C., Shim H., Kim S., Li Q., Reddy R., Mukherjee M., Xu Y., Wonsey D., Lee L.A., Dang C.V. Deregulation of glucose transporter 1 and glycolytic gene expression by c-Myc. J. Biol. Chem. 2000, 275:21797-21800.
32. Pike L.S., Smift A.L., Croteau N.J., Ferrick D.A., Wu M. Inhibition of fatty acid oxidation by etomoxir impairs NADPH production and increases reactive oxygen species resulting in ATP depletion and cell death in human glioblastoma cells. Biochim. Biophys. Acta. 2011, 1807:726-734.
33. Shim H., Dolde C., Lewis B.C., Wu C.S., Dang G., Jungmann R.A., Dalla-Favera R., Dang C.V. c-Myc transactivation of LDH-A: implications for tumor metabolism and growth. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:6658-6663.
34. David C.J., Chen M., Assanah M., Canoll P., Manley J.L. HnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancer. Nature 2010, 463:364-368.
35. Christofk H.R., Vander H.M., Harris M.H., Ramanathan A., Gerszten R.E., Wei R., Fleming M.D., Schreiber S.L., Cantley L.C. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 2008, 452:230-233.
36. Kim J.W., Gao P., Liu Y.C., Semenza G.L., Dang C.V. Hypoxia-inducible factor 1 and dysregulated c-Myc cooperatively induce vascular endothelial growth factor and metabolic switches hexokinase 2 and pyruvate dehydrogenase kinase 1. Mol. Cell. Biol. 2007, 27:7381-7393.
37. Lewis B.C., Prescott J.E., Campbell S.E., Shim H., Orlowski R.Z., Dang C.V. Tumor induction by the c-Myc target genes rcl and lactate dehydrogenase A. Cancer Res. 2000, 60:6178-6183.
38. Shim H., Chun Y.S., Lewis B.C., Dang C.V. A unique glucose-dependent apoptotic pathway induced by c-Myc. Proc. Natl. Acad. Sci. U S A. 1998, 95:1511-1516.
39. Morrish F., Isern N., Sadilek M., Jeffrey M., Hockenbery D.M. c-Myc activates multiple metabolic networks to generate substrates for cell-cycle entry. Oncogene 2009, 28:2485-2491.
40. Camarero N., Mascaro C., Mayordomo C., Vilardell F., Haro D., Marrero P.F. Ketogenic HMGCS2 Is a c-Myc target gene expressed in differentiated cells of human colonic epithelium and down-regulated in colon cancer. Mol. Cancer Res. 2006, 4:645-653.
41. Telang N.T., Arcuri F., Granata O.M., Bradlow H.L., Osborne M.P., Castagnetta L. Alteration of oestradiol metabolism in myc oncogene-transfected mouse mammary epithelial cells. Br. J. Cancer 1998, 77:1549-1554.
42. Dang C.V., Le A., Gao P. MYC-induced cancer cell energy metabolism and therapeutic opportunities. Clin. Cancer Res. 2009, 15:6479-6483.
43. Liu Y.C., Li F., Handler J., Huang C.R., Xiang Y., Neretti N., Sedivy J.M., Zeller K.I., Dang C.V. Global regulation of nucleotide biosynthetic genes by c-Myc. PLoS One 2008, 3:e2722.
44. Mannava S., Grachtchouk V., Wheeler L.J., Im M., Zhuang D., Slavina E.G., Mathews C.K., Shewach D.S., Nikiforov M.A. Direct role of nucleotide metabolism in C-MYC-dependent proliferation of melanoma cells. Cell Cycle 2008, 7:2392-2400.
45. Vafa O., Wade M., Kern S., Beeche M., Pandita T.K., Hampton G.M., Wahl G.M. c-Myc can induce DNA damage, increase reactive oxygen species, and mitigate p53 function: a mechanism for oncogene-induced genetic instability. Mol. Cell 2002, 9:1031-1044.
46. Telang S., Yalcin A., Clem A.L., Bucala R., Lane A.N., Eaton J.W., Chesney J. Ras transformation requires metabolic control by 6-phosphofructo-2-kinase. Oncogene 2006, 25:7225-7234.
47. Weinberg F., Hamanaka R., Wheaton W.W., Weinberg S., Joseph J., Lopez M., Kalyanaraman B., Mutlu G.M., Budinger G.R., Chandel N.S. Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:8788-8793.
48. Vizan P., Boros L.G., Figueras A., Capella G., Mangues R., Bassilian S., Lim S., Lee W.N., Cascante M. K-ras codon-specific mutations produce distinctive metabolic phenotypes in NIH3T3 mice [corrected] fibroblasts. Cancer Res. 2005, 65:5512-5515.
49. Hu Y., Lu W., Chen G., Wang P., Chen Z., Zhou Y., Ogasawara M., Trachootham D., Feng L., Pelicano H., Chiao P.J., Keating M.J., Garcia-Manero G., Huang P. K-ras(G12V) transformation leads to mitochondrial dysfunction and a metabolic switch from oxidative phosphorylation to glycolysis. Cell Res. 2012, 22:399-412.
50. Huang M., Chida K., Kamata N., Nose K., Kato M., Homma Y., Takenawa T., Kuroki T. Enhancement of inositol phospholipid metabolism and activation of protein kinase C in ras-transformed rat fibroblasts. J. Biol. Chem. 1988, 263:17975-17980.
51. Alonso T., Morgan R.O., Marvizon J.C., Zarbl H., Santos E. Malignant transformation by ras and other oncogenes produces common alterations in inositol phospholipid signaling pathways. Proc. Natl. Acad. Sci. U. S. A. 1988, 85:4271-4275.
52. Yu C.L., Tsai M.H., Stacey D.W. Cellular ras activity and phospholipid metabolism. Cell 1988, 52:63-71.
53. Gaglio D., Metallo C.M., Gameiro P.A., Hiller K., Danna L.S., Balestrieri C., Alberghina L., Stephanopoulos G., Chiaradonna F. Oncogenic K-Ras decouples glucose and glutamine metabolism to support cancer cell growth. Mol. Syst. Biol. 2011, 7:523.
54. Fan Y., Dickman K.G., Zong W.X. Akt and c-Myc differentially activate cellular metabolic programs and prime cells to bioenergetic inhibition. J. Biol. Chem. 2010, 285:7324-7333.
55. Karni R., Dor Y., Keshet E., Meyuhas O., Levitzki A. Activated pp 60c-Src leads to elevated hypoxia-inducible factor (HIF)-1alpha expression under normoxia. J. Biol. Chem. 2002, 277:42919-42925.
56. Hebert-Chatelain E., Jose C., Gutierrez C.N., Dupuy J.W., Rocher C., Dachary-Prigent J., Letellier T. Preservation of NADH ubiquinone-oxidoreductase activity by Src kinase-mediated phosphorylation of NDUFB10. Biochim. Biophys. Acta 2012, 1817:718-725.
57. Geary C.G. The story of chronic myeloid leukaemia. Br. J. Haematol. 2000, 110:2-11.
58. Tandon P., Gallo C.A., Khatri S., Barger J.F., Yepiskoposyan H., Plas D.R. Requirement for ribosomal protein S6 kinase 1 to mediate glycolysis and apoptosis resistance induced by Pten deficiency. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:2361-2365.
59. Duvel K., Yecies J.L., Menon S., Raman P., Lipovsky A.I., Souza A.L., Triantafellow E., Ma Q., Gorski R., Cleaver S., Vander H.M., MacKeigan J.P., Finan P.M., Clish C.B., Murphy L.O., Manning B.D. Activation of a metabolic gene regulatory network downstream of mTOR complex 1. Mol. Cell 2010, 39:171-183.
60. Barger J.F., Gallo C.A., Tandon P., Liu H., Sullivan A., Grimes H.L., Plas D.R. S6K1 determines the metabolic requirements for BCR-ABL survival. Oncogene 2013, 32:453-461.
61. Langevin F., Crossan G.P., Rosado I.V., Arends M.J., Patel K.J. Fancd2 counteracts the toxic effects of naturally produced aldehydes in mice. Nature 2011, 475:53-58.
62. Daye D., Wellen K.E. Metabolic reprogramming in cancer: unraveling the role of glutamine in tumorigenesis. Semin. Cell Dev. Biol. 2012, 23:362-369.
63. Wise D.R., DeBerardinis R.J., Mancuso A., Sayed N., Zhang X.Y., Pfeiffer H.K., Nissim I., Daikhin E., Yudkoff M., McMahon S.B., Thompson C.B. Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:18782-18787.
64. Liu W., Le A., Hancock C., Lane A.N., Dang C.V., Fan T.W., Phang J.M. Reprogramming of proline and glutamine metabolism contributes to the proliferative and metabolic responses regulated by oncogenic transcription factor c-MYC. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:8983-8988.
65. Morrish F., Noonan J., Perez-Olsen C., Gafken P.R., Fitzgibbon M., Kelleher J., VanGilst M., Hockenbery D. Myc-dependent mitochondrial generation of acetyl-CoA contributes to fatty acid biosynthesis and histone acetylation during cell cycle entry. J. Biol. Chem. 2010, 285:36267-36274.
66. Gao P., Tchernyshyov I., Chang T.C., Lee Y.S., Kita K., Ochi T., Zeller K.I., De Marzo A.M., Van Eyk J.E., Mendell J.T., Dang C.V. c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature 2009, 458:762-765.
67. Keijer J J., Bekkenkamp-Grovenstein M., Venema D., Dommels Y.E. Bioactive food components, cancer cell growth limitation and reversal of glycolytic metabolism. Biochim. Biophys. Acta 2011, 1807:697-706.
68. Dang C.V. Therapeutic targeting of myc-reprogrammed cancer cell metabolism. Cold Spring Harb. Symp. Quant. Biol. 2011, 76:369-374.
69. Jose C., Bellance N., Rossignol R. Choosing between glycolysis and oxidative phosphorylation: a tumor's dilemma?. Biochim. Biophys. Acta. 2011, 1807:552-561.
70. DeBerardinis R.J., Mancuso A., Daikhin E., Nissim I., Yudkoff M., Wehrli S., Thompson C.B. Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:19345-19350.
71. Jain M., Nilsson R., Sharma S., Madhusudhan N., Kitami T., Souza A.L., Kafri R., Kirschner M.W., Clish C.B., Mootha V.K. Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation. Science 2012, 336:1040-1044.
72. Martinez-Outschoorn U.E., Pestell R.G., Howell A., Tykocinski M.L., Nagajyothi F., Machado F.S., Tanowitz H.B., Sotgia F., Lisanti M.P. Energy transfer in "parasitic" cancer metabolism: mitochondria are the powerhouse and Achilles' heel of tumor cells. Cell Cycle 2011, 10:4208-4216.
73. Kranendijk M., Struys E.A., van Schaftingen E., Gibson K.M., Kanhai W.A., van der Knaap M.S., Amiel J., Buist N.R., Das A.M., de Klerk J.B., Feigenbaum A.S., Grange D.K., Hofstede F.C., Holme E., Kirk E.P., Korman S.H., Morava E., Morris A., Smeitink J., Sukhai R.N., Vallance H., Jakobs C., Salomons G.S. IDH2 mutations in patients with D-2-hydroxyglutaric aciduria. Science 2010, 330:336.
74. Dang L., White D.W., Gross S., Bennett B.D., Bittinger M.A., Driggers E.M., Fantin V.R., Jang H.G., Jin S., Keenan M.C., Marks K.M., Prins R.M., Ward P.S., Yen K.E., Liau L.M., Rabinowitz J.D., Cantley L.C., Thompson C.B., Vander H.M., Su S.M. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2009, 462:739-744.
75. Yan H., Parsons D.W., Jin G., McLendon R., Rasheed B.A., Yuan W., Kos I., Batinic-Haberle I., Jones S., Riggins G.J., Friedman H., Friedman A., Reardon D., Herndon J., Kinzler K.W., Velculescu V.E., Vogelstein B., Bigner D.D. IDH1 and IDH2 mutations in gliomas. N. Engl. J. Med. 2009, 360:765-773.
76. Bleeker F.E., Lamba S., Leenstra S., Troost D., Hulsebos T., Vandertop W.P., Frattini M., Molinari F., Knowles M., Cerrato A., Rodolfo M., Scarpa A., Felicioni L., Buttitta F., Malatesta S., Marchetti A., Bardelli A. IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors. Hum. Mutat. 2009, 30:7-11.
77. Figueroa M.E., Abdel-Wahab O., Lu C., Ward P.S., Patel J., Shih A., Li Y., Bhagwat N., Vasanthakumar A., Fernandez H.F., Tallman M.S., Sun Z., Wolniak K., Peeters J.K., Liu W., Choe S.E., Fantin V.R., Paietta E., Lowenberg B., Licht J.D., Godley L.A., Delwel R., Valk P.J., Thompson C.B., Levine R.L., Melnick A. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 2010, 18:553-567.
78. Marcucci G., Maharry K., Wu Y.Z., Radmacher M.D., Mrozek K., Margeson D., Holland K.B., Whitman S.P., Becker H., Schwind S., Metzeler K.H., Powell B.L., Carter T.H., Kolitz J.E., Wetzler M., Carroll A.J., Baer M.R., Caligiuri M.A., Larson R.A., Bloomfield C.D. IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study. J. Clin. Oncol. 2010, 28:2348-2355.
79. Hemerly J.P., Bastos A.U., Cerutti J.M. Identification of several novel non-p.R132 IDH1 variants in thyroid carcinomas. Eur. J. Endocrinol. 2010, 163:747-755.
80. Amary M.F., Bacsi K., Maggiani F., Damato S., Halai D., Berisha F., Pollock R., O'Donnell P., Grigoriadis A., Diss T., Eskandarpour M., Presneau N., Hogendoorn P.C., Futreal A., Tirabosco R., Flanagan A.M. IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours. J. Pathol. 2011, 224:334-343.
81. Luchman H.A., Stechishin O.D., Dang N.H., Blough M.D., Chesnelong C., Kelly J.J., Nguyen S.A., Chan J.A., Weljie A.M., Cairncross J.G., Weiss S. An in vivo patient-derived model of endogenous IDH1-mutant glioma. Neuro Oncol. 2012, 14:184-191.
82. Ward P.S., Cross J.R., Lu C., Weigert O., Abel-Wahab O., Levine R.L., Weinstock D.M., Sharp K.A., Thompson C.B. Identification of additional IDH mutations associated with oncometabolite R(-)-2-hydroxyglutarate production. Oncogene 2012, 31:2491-2498.
83. Gross S., Cairns R.A., Minden M.D., Driggers E.M., Bittinger M.A., Jang H.G., Sasaki M., Jin S., Schenkein D.P., Su S.M., Dang L., Fantin V.R., Mak T.W. Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. J. Exp. Med. 2010, 207:339-344.
84. Jin G., Reitman Z.J., Spasojevic I., Batinic-Haberle I., Yang J., Schmidt-Kittler O., Bigner D.D., Yan H. 2-hydroxyglutarate production, but not dominant negative function, is conferred by glioma-derived NADP-dependent isocitrate dehydrogenase mutations. PLoS One 2011, 6:e16812.
85. Xu W., Yang H., Liu Y., Yang Y., Wang P., Kim S.H., Ito S., Yang C., Wang P., Xiao M.T., Liu L.X., Jiang W.Q., Liu J., Zhang J.Y., Wang B., Frye S., Zhang Y., Xu Y.H., Lei Q.Y., Guan K.L., Zhao S.M., Xiong Y. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases. Cancer Cell 2011, 19:17-30.
86. Lu C., Ward P.S., Kapoor G.S., Rohle D., Turcan S., Abdel-Wahab O., Edwards C.R., Khanin R., Figueroa M.E., Melnick A., Wellen K.E., O'Rourke D.M., Berger S.L., Chan T.A., Levine R.L., Mellinghoff I.K., Thompson C.B. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature 2012, 483:474-478.
87. Sasaki M., Knobbe C.B., Munger J.C., Lind E.F., Brenner D., Brustle A., Harris I.S., Holmes R., Wakeham A., Haight J., You-Ten A., Li W.Y., Schalm S., Su S.M., Virtanen C., Reifenberger G., Ohashi P.S., Barber D.L., Figueroa M.E., Melnick A., Zuniga-Pflucker J.C., Mak T.W. IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics. Nature 2012, 488:656-659.
88. Koivunen P., Lee S., Duncan C.G., Lopez G., Lu G., Ramkissoon S., Losman J.A., Joensuu P., Bergmann U., Gross S., Travins J., Weiss S., Looper R., Ligon K.L., Verhaak R.G., Yan H., Kaelin W.J. Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation. Nature 2012, 483:484-488.
89. Martinez-Outschoorn U.E., Prisco M., Ertel A., Tsirigos A., Lin Z., Pavlides S., Wang C., Flomenberg N., Knudsen E.S., Howell A., Pestell R.G., Sotgia F., Lisanti M.P. Ketones and lactate increase cancer cell "stemness," driving recurrence, metastasis and poor clinical outcome in breast cancer: achieving personalized medicine via Metabolo-Genomics. Cell Cycle 2011, 10:1271-1286.
90. Hirschhaeuser F., Sattler U.G., Mueller-Klieser W. Lactate: a metabolic key player in cancer. Cancer Res. 2011, 71:6921-6925.
91. Whitaker-Menezes D., Martinez-Outschoorn U.E., Lin Z., Ertel A., Flomenberg N., Witkiewicz A.K., Birbe R.C., Howell A., Pavlides S., Gandara R., Pestell R.G., Sotgia F., Philp N.J., Lisanti M.P. Evidence for a stromal-epithelial "lactate shuttle" in human tumors: MCT4 is a marker of oxidative stress in cancer-associated fibroblasts. Cell Cycle 2011, 10:1772-1783.
92. Rattigan Y.I., Patel B.B., Ackerstaff E., Sukenick G., Koutcher J.A., Glod J.W., Banerjee D. Lactate is a mediator of metabolic cooperation between stromal carcinoma associated fibroblasts and glycolytic tumor cells in the tumor microenvironment. Exp. Cell Res. 2012, 318:326-335.
93. Opitz C.A., Litzenburger U.M., Sahm F., Ott M., Tritschler I., Trump S., Schumacher T., Jestaedt L., Schrenk D., Weller M., Jugold M., Guillemin G.J., Miller C.L., Lutz C., Radlwimmer B., Lehmann I., von Deimling A., Wick W., Platten M. An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature 2011, 478:197-203.
94. Prendergast G.C. Cancer: why tumours eat tryptophan. Nature 2011, 478:192-194.
95. de Jong R.A., Nijman H.W., Boezen H.M., Volmer M., Ten H.K., Krijnen J., van der Zee A.G., Hollema H., Kema I.P. Serum tryptophan and kynurenine concentrations as parameters for indoleamine 2,3-dioxygenase activity in patients with endometrial, ovarian, and vulvar cancer. Int. J. Gynecol. Cancer 2011, 21:1320-1327.
96. Lyon D.E., Walter J.M., Starkweather A.R., Schubert C.M., McCain N.L. Tryptophan degradation in women with breast cancer: a pilot study. BMC Res. Notes 2011, 4:156.
97. Singh P.K., Brand R.E., Mehla K. MicroRNAs in pancreatic cancer metabolism. Nat. Rev. Gastroenterol. Hepatol. 2012, 9:334-344.
98. Guttilla I.K., White B.A. Coordinate regulation of FOXO1 by miR-27a, miR-96, and miR-182 in breast cancer cells. J. Biol. Chem. 2009, 284:23204-23216.
99. Medina P.P., Nolde M., Slack F.J. OncomiR addiction in an in vivo model of microRNA-21-induced pre-B-cell lymphoma. Nature 2010, 467:86-90.
100. Yu Y., Kanwar S.S., Patel B.B., Oh P.S., Nautiyal J., Sarkar F.H., Majumdar A.P. MicroRNA-21 induces stemness by downregulating transforming growth factor beta receptor 2 (TGFbetaR2) in colon cancer cells. Carcinogenesis 2012, 33:68-76.
101. Koide N., Yasuda K., Kadomatsu K., Takei Y. Establishment and optimal culture conditions of microrna-induced pluripotent stem cells generated from HEK293 cells via transfection of microrna-302s expression vector. Nagoya J. Med. Sci. 2012, 74:157-165.
102. Boutz D.R., Collins P.J., Suresh U., Lu M., Ramirez C.M., Fernandez-Hernando C., Huang Y., Abreu R.S., SY Le, Shapiro B.A., Liu A.M., Luk J.M., Aldred S.F., Trinklein N.D., Marcotte E.M., Penalva L.O. Two-tiered approach identifies a network of cancer and liver disease-related genes regulated by miR-122. J. Biol. Chem. 2011, 286:18066-18078.
103. Burchard J., Zhang C., Liu A.M., Poon R.T., Lee N.P., Wong K.F., Sham P.C., Lam B.Y., Ferguson M.D., Tokiwa G., Smith R., Leeson B., Beard R., Lamb J.R., Lim L., Mao M., Dai H., Luk J.M. microRNA-122 as a regulator of mitochondrial metabolic gene network in hepatocellular carcinoma. Mol. Syst. Biol. 2010, 6:402.
104. Peschiaroli A., Giacobbe A., Formosa A., Markert E.K., Bongiorno-Borbone L., Levine A.J., Candi E., D'Alessandro A., Zolla L., Finazzi A.A., Melino G. miR-143 regulates hexokinase 2 expression in cancer cells. Oncogene 2013, 32:797-802.
105. Zhai H., Song B., Xu X., Zhu W., Ju J. Inhibition of autophagy and tumor growth in colon cancer by miR-502. Oncogene 2013, 32:1570-1579.
106. Zou C., Xu Q., Mao F., Li D., Bian C., Liu L.Z., Jiang Y., Chen X., Qi Y., Zhang X., Wang X., Sun Q., Kung H.F., Lin M.C., Dress A., Wardle F., Jiang B.H., Lai L. MiR-145 inhibits tumor angiogenesis and growth by N-RAS and VEGF. Cell Cycle 2012, 11:2137-2145.
107. Kim H.R., Roe J.S., Lee J.E., Hwang I.Y., Cho E.J., Youn H.D. A p53-inducible microRNA-34a downregulates Ras signaling by targeting IMPDH. Biochem. Biophys. Res. Commun. 2012, 418:682-688.
108. Yang X., Lin X., Zhong X., Kaur S., Li N., Liang S., Lassus H., Wang L., Katsaros D., Montone K., Zhao X., Zhang Y., Butzow R., Coukos G., Zhang L. Double-negative feedback loop between reprogramming factor LIN28 and microRNA let-7 regulates aldehyde dehydrogenase 1-positive cancer stem cells. Cancer Res. 2010, 70:9463-9472.
109. Kefas B., Comeau L., Erdle N., Montgomery E., Amos S., Purow B. Pyruvate kinase M2 is a target of the tumor-suppressive microRNA-326 and regulates the survival of glioma cells. Neuro Oncol. 2010, 12:1102-1112.
110. Aumiller V., Förstemann K. Roles of microRNAs beyond development-metabolism and neural plasticity. Biochim. Biophys. Acta. 2008, 1779:692-696.
111. Mutallip M., Nohata N., Hanazawa T., Kikkawa N., Horiguchi S., Fujimura L., Kawakami K., Chiyomaru T., Enokida H., Nakagawa M., Okamoto Y., Seki N. Glutathione S-transferase P1 (GSTP1) suppresses cell apoptosis and its regulation by miR-133alpha in head and neck squamous cell carcinoma (HNSCC). Int. J. Mol. Med. 2011, 27:345-352.
112. Fang R., Xiao T., Fang Z., Sun Y., Li F., Gao Y., Feng Y., Li L., Wang Y., Liu X., Chen H., Liu X.Y., Ji H. MicroRNA-143 (miR-143) regulates cancer glycolysis via targeting hexokinase 2 gene. J. Biol. Chem. 2012, 287:23227-23235.
113. Gregersen L.H., Jacobsen A., Frankel L.B., Wen J., Krogh A., Lund A.H. microRNA-143 down-regulates hexokinase 2 in colon cancer cells. BMC Cancer 2012, 12:232.
114. Kaller M., Liffers S.T., Oeljeklaus S., Kuhlmann K., Roh S., Hoffmann R., Warscheid B., Hermeking H. Genome-wide characterization of miR-34a induced changes in protein and mRNA expression by a combined pulsed SILAC and microarray analysis. Mol. Cell. Proteomics 2011, 10:M111-M10462.
115. Cheng J., Guo J.M., Xiao B.X., Miao Y., Jiang Z., Zhou H., Li Q.N. piRNA, the new non-coding RNA, is aberrantly expressed in human cancer cells. Clin. Chim. Acta 2011, 412:1621-1625.
116. Siddiqi S., Matushansky I. Piwis and piwi-interacting RNAs in the epigenetics of cancer. J. Cell. Biochem. 2012, 113:373-380.
117. Ye Y., Yin D.T., Chen L., Zhou Q., Shen R., He G., Yan Q., Tong Z., Issekutz A.C., Shapiro C.L., Barsky S.H., Lin H., Li J.J., Gao J.X. Identification of Piwil2-like (PL2L) proteins that promote tumorigenesis. PLoS One 2010, 5:e13406.
118. Siddiqi S., Terry M., Matushansky I. Hiwi mediated tumorigenesis is associated with DNA hypermethylation. PLoS One 2012, 7:e33711.
119. Yin D.T., Wang Q., Chen L., Liu M.Y., Han C., Yan Q., Shen R., He G., Duan W., Li J.J., Wani A., Gao J.X. Germline stem cell gene PIWIL2 mediates DNA repair through relaxation of chromatin. PLoS One 2011, 6:e27154.
120. Goda N., Kanai M. Hypoxia-inducible factors and their roles in energy metabolism. Int. J. Hematol. 2012, 95:457-463.
121. Zhou W., Choi M., Margineantu D., Margaretha L., Hesson J., Cavanaugh C., Blau C.A., Horwitz M.S., Hockenbery D., Ware C., Ruohola-Baker H. HIF1alpha induced switch from bivalent to exclusively glycolytic metabolism during ESC-to-EpiSC/hESC transition. EMBO J. 2012, 31:2103-2116.
122. Ma Y., Liang D., Liu J., Axcrona K., Kvalheim G., Stokke T., Nesland J.M., Suo Z. Prostate cancer cell lines under hypoxia exhibit greater stem-like properties. PLoS One 2011, 6:e29170.
123. Liang D., Ma Y., Liu J., Trope C.G., Holm R., Nesland J.M., Suo Z. The hypoxic microenvironment upgrades stem-like properties of ovarian cancer cells. BMC Cancer 2012, 12:201.
124. Sun C., Song H., Zhang H., Hou C., Zhai T., Huang L., Zhang L. CD133 expression in renal cell carcinoma (RCC) is correlated with nuclear hypoxia-inducing factor 1alpha (HIF-1alpha). J. Cancer Res. Clin. Oncol. 2012, 138:1619-1624.
125. Icard P., Lincet H. A global view of the biochemical pathways involved in the regulation of the metabolism of cancer cells. Biochim. Biophys. Acta. 2012, 1826:423-433.
126. Mazzio E.A., Boukli N., Rivera N., Soliman K.F. Pericellular pH homeostasis is a primary function of the Warburg effect: inversion of metabolic systems to control lactate steady state in tumor cells. Cancer Sci. 2012, 103:422-432.
127. Sen N., Satija Y.K., Das S. p53 and metabolism: old player in a new game. Transcription 2012, 3:119-123.
128. Habib S.L., Yadav A., Mahimainathan L., Valente A.J. Regulation of PI 3-K, PTEN, p53, and mTOR in malignant and benign tumors deficient in tuberin. Genes Cancer 2011, 2:1051-1060.
129. Chen J.Q., Russo J. Dysregulation of glucose transport, glycolysis, TCA cycle and glutaminolysis by oncogenes and tumor suppressors in cancer cells. Biochim Biophys Acta. 2012, 1826:370-384.
130. Song M.S., Salmena L., Pandolfi P.P. The functions and regulation of the PTEN tumour suppressor. Nat. Rev. Mol. Cell Biol. 2012, 13:283-296.
131. Garcia-Cao I., Song M.S., Hobbs R.M., Laurent G., Giorgi C., de Boer V.C., Anastasiou D., Ito K., Sasaki A.T., Rameh L., Carracedo A., Vander H.M., Cantley L.C., Pinton P., Haigis M.C., Pandolfi P.P. Systemic elevation of PTEN induces a tumor-suppressive metabolic state. Cell 2012, 149:49-62.
132. Liu J., Feng Z. PTEN, energy metabolism and tumor suppression. Acta Biochim. Biophys. Sin. (Shanghai) 2012, 44:629-631.
133. Krzeslak A. Akt kinase: a key regulator of metabolism and progression of tumors. Postepy Hig. Med. Dosw. (Online) 2010, 64:490-503.
134. Mulholland D.J., Kobayashi N., Ruscetti M., Zhi A., Tran L.M., Huang J., Gleave M., Wu H. Pten loss and RAS/MAPK activation cooperate to promote EMT and metastasis initiated from prostate cancer stem/progenitor cells. Cancer Res. 2012, 72:1878-1889.
135. Sebbagh M., Olschwang S., Santoni M.J., Borg J.P. The LKB1 complex-AMPK pathway: the tree that hides the forest. Fam. Cancer 2011, 10:415-424.
136. Green A.S., Chapuis N., Lacombe C., Mayeux P., Bouscary D., Tamburini J. LKB1/AMPK/mTOR signaling pathway in hematological malignancies: from metabolism to cancer cell biology. Cell Cycle 2011, 10:2115-2120.
137. Partanen J.I., Tervonen T.A., Myllynen M., Lind E., Imai M., Katajisto P., Dijkgraaf G.J., Kovanen P.E., Makela T.P., Werb Z., Klefstrom J. Tumor suppressor function of Liver kinase B1 (Lkb1) is linked to regulation of epithelial integrity. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:E388-E397.
138. Shorning B.Y., Clarke A.R. LKB1 loss of function studied in vivo. FEBS Lett. 2011, 585:958-966.
139. Gurumurthy S., Xie S.Z., Alagesan B., Kim J., Yusuf R.Z., Saez B., Tzatsos A., Ozsolak F., Milos P., Ferrari F., Park P.J., Shirihai O.S., Scadden D.T., Bardeesy N. The Lkb1 metabolic sensor maintains haematopoietic stem cell survival. Nature 2010, 468:659-663.
140. Gu Y., Lin S., Li J.L., Nakagawa H., Chen Z., Jin B., Tian L., Ucar D.A., Shen H., Lu J., Hochwald S.N., Kaye F.J., Wu L. Altered LKB1/CREB-regulated transcription co-activator (CRTC) signaling axis promotes esophageal cancer cell migration and invasion. Oncogene 2012, 31:469-479.
141. Linher-Melville K., Zantinge S., Singh G. Liver kinase B1 expression (LKB1) is repressed by estrogen receptor alpha (ERalpha) in MCF-7 human breast cancer cells. Biochem. Biophys. Res. Commun. 2012, 417:1063-1068.
142. Kline E.R., Muller S., Pan L., Tighiouart M., Chen Z.G., Marcus A.I. Localization-specific LKB1 loss in head and neck squamous cell carcinoma metastasis. Head Neck 2011, 33:1501-1512.
143. Sanchez-Cespedes M. The role of LKB1 in lung cancer. Fam. Cancer 2011, 10:447-453.
144. Herrmann J.L., Byekova Y., Elmets C.A., Athar M. Liver kinase B1 (LKB1) in the pathogenesis of epithelial cancers. Cancer Lett. 2011, 306:1-9.
145. Gao Y., Ge G., Ji H. LKB1 in lung cancerigenesis: a serine/threonine kinase as tumor suppressor. Protein Cell 2011, 2:99-107.
146. de Wilde R.F., Ottenhof N.A., Jansen M., Morsink F.H., de Leng W.W., Offerhaus G.J., Brosens L.A. Analysis of LKB1 mutations and other molecular alterations in pancreatic acinar cell carcinoma. Mod. Pathol. 2011, 24:1229-1236.
147. Gao Y., Xiao Q., Ma H., Li L., Liu J., Feng Y., Fang Z., Wu J., Han X., Zhang J., Sun Y., Wu G., Padera R., Chen H., Wong K.K., Ge G., Ji H. LKB1 inhibits lung cancer progression through lysyl oxidase and extracellular matrix remodeling. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:18892-18897.
148. Carling D., Thornton C., Woods A., Sanders M.J. AMP-activated protein kinase: new regulation, new roles?. Biochem. J. 2012, 445:11-27.
149. Svensson R.U., Shaw R.J. Cancer metabolism: tumour friend or foe. Nature 2012, 485:590-591.
150. Jeon S.M., Chandel N.S., Hay N. AMPK regulates NADPH homeostasis to promote tumour cell survival during energy stress. Nature 2012, 485:661-665.
151. Inoki K., Kim J., Guan K.L. AMPK and mTOR in cellular energy homeostasis and drug targets. Annu. Rev. Pharmacol. Toxicol. 2012, 52:381-400.
152. Hardie D.G. AMP-activated protein kinase: an energy sensor that regulates all aspects of cell function. Genes Dev. 2011, 25:1895-1908.
153. Xiao B., Sanders M.J., Underwood E., Heath R., Mayer F.V., Carmena D., Jing C., Walker P.A., Eccleston J.F., Haire L.F., Saiu P., Howell S.A., Aasland R., Martin S.R., Carling D., Gamblin S.J. Structure of mammalian AMPK and its regulation by ADP. Nature 2011, 472:230-233.
154. Krock B., Skuli N., Simon M.C. The tumor suppressor LKB1 emerges as a critical factor in hematopoietic stem cell biology. Cell Metab. 2011, 13:8-10.
155. Andrade B.M., Cazarin J.M., Zancan P., Carvalho D.M.D. Amp-activated protein kinase up regulates glucose uptake in thyroid pccl3 cells independent of thyrotropin. Thyroid 2012, 22:1063-1068.
156. Vakana E., Platanias L.C. AMPK in BCR-ABL expressing leukemias. Regulatory effects and therapeutic implications. Oncotarget 2011, 2:1322-1328.
157. Vakana E., Altman J.K., Glaser H., Donato N.J., Platanias L.C. Antileukemic effects of AMPK activators on BCR-ABL-expressing cells. Blood 2011, 118:6399-6402.
158. Mair W., Morantte I., Rodrigues A.P., Manning G., Montminy M., Shaw R.J., Dillin A. Lifespan extension induced by AMPK and calcineurin is mediated by CRTC-1 and CREB. Nature 2011, 470:404-408.
159. William W.N., Kim J.S., Liu D.D., Solis L., Behrens C., Lee J.J., Lippman S.M., Kim E.S., Hong W.K., Wistuba I.I., Lee H.Y. The impact of phosphorylated AMP-activated protein kinase expression on lung cancer survival. Ann. Oncol. 2012, 23:78-85.
160. Lee C.W., Wong L.L., Tse E.Y., Liu H.F., Leong V.Y., Lee J.M., Hardie D.G., Ng I.O., Ching Y.P. AMPK promotes p53 acetylation via phosphorylation and inactivation of SIRT1 in liver cancer cells. Cancer Res. 2012, 72:4394-4404.
161. Martinez-Reyes I., Sanchez-Arago M., Cuezva J.M. AMPK and GCN2-ATF4 signal the repression of mitochondria in colon cancer cells. Biochem. J. 2012, 444:249-259.
162. Kim Y.H., Liang H., Liu X., Lee J.S., Cho J.Y., Cheong J.H., Kim H., Li M., Downey T.J., Dyer M.D., Sun Y., Sun J., Beasley E.M., Chung H.C., Noh S.H., Weinstein J.N., Liu C.G., Powis G. AMPKalpha modulation in cancer progression: multilayer integrative analysis of the whole transcriptome in Asian gastric cancer. Cancer Res. 2012, 72:2512-2521.
163. Tong W.H., Sourbier C., Kovtunovych G., Jeong S.Y., Vira M., Ghosh M., Romero V.V., Sougrat R., Vaulont S., Viollet B., Kim Y.S., Lee S., Trepel J., Srinivasan R., Bratslavsky G., Yang Y., Linehan W.M., Rouault T.A. The glycolytic shift in fumarate-hydratase-deficient kidney cancer lowers AMPK levels, increases anabolic propensities and lowers cellular iron levels. Cancer Cell 2011, 20:315-327.
164. Buckendahl A.C., Budczies J., Fiehn O., Darb-Esfahani S., Kind T., Noske A., Weichert W., Sehouli J., Braicu E., Dietel M., Denkert C. Prognostic impact of AMP-activated protein kinase expression in ovarian carcinoma: correlation of protein expression and GC/TOF-MS-based metabolomics. Oncol. Rep. 2011, 25:1005-1012.
165. Fogarty S., Hardie D.G. Development of protein kinase activators: AMPK as a target in metabolic disorders and cancer. Biochim. Biophys. Acta. 2010, 1804:581-591.
166. Hardie D.G. Adenosine monophosphate-activated protein kinase: a central regulator of metabolism with roles in diabetes, cancer, and viral infection. Cold Spring Harb. Symp. Quant. Biol. 2011, 76:155-164.
167. Hardie D.G. AMP-activated protein kinase: a cellular energy sensor with a key role in metabolic disorders and in cancer. Biochem. Soc. Trans. 2011, 39:1-13.
168. Becker S., Dossus L., Kaaks R. Obesity related hyperinsulinaemia and hyperglycaemia and cancer development. Arch. Physiol. Biochem. 2009, 115:86-96.
169. Li D. Metformin as an antitumor agent in cancer prevention and treatment. J. Diabetes 2011, 3:320-327.
170. Vazquez-Martin A., Oliveras-Ferraros C., Cufi S., Martin-Castillo B., Menendez J.A. Metformin and energy metabolism in breast cancer: from insulin physiology to tumour-initiating stem cells. Curr. Mol. Med. 2010, 10:674-691.